Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 305 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Follow-Up Questions
Who is the CEO of Bicycle Therapeutics PLC?
Dr. Kevin Lee is the Chief Executive Officer of Bicycle Therapeutics PLC, joining the firm since 2015.
What is the price performance of BCYC stock?
The current price of BCYC is $6.97, it has decreased 2.65% in the last trading day.
What are the primary business themes or industries for Bicycle Therapeutics PLC?
Bicycle Therapeutics PLC belongs to Biotechnology industry and the sector is Health Care
What is Bicycle Therapeutics PLC market cap?
Bicycle Therapeutics PLC's current market cap is $483.0M
Is Bicycle Therapeutics PLC a buy, sell, or hold?
According to wall street analysts, 14 analysts have made analyst ratings for Bicycle Therapeutics PLC, including 6 strong buy, 10 buy, 4 hold, 0 sell, and 6 strong sell
